Clearmind Medicine Inc. (CMND) stock
CMNDNasdaqPharmaceutical PreparationsFiscal year ends October 31
Financials through Q3 FY2026, quarter ended Jul 31, 2026Score 5/30
$4.62−0.33 (-6.67%)
Close on Nov 12, 2026Market cap $730.31KP/E –Yield –
Clearmind Medicine EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -$30.35. The highest annual figure on record is -$30.35 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -$30.35 | – |
| FY2024 | Oct 31, 2024 | -$67.80 | – |
| FY2023 | Oct 31, 2023 | -$1703.04 | – |
| FY2022 | Oct 31, 2022 | -$6364.40 | – |
| FY2021 | Oct 31, 2021 | -$3526.40 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -$0.57 | – |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | -$6.78 | – |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -$3.32 | – |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -$96.73 | – |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -$62.27 | – |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -$9.55 | – |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -$23.60 | – |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -$11.20 | – |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -$36.00 | – |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | -$97.20 | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | -$664.80 | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | -$992.00 | – |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | -$2136.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?